Calidi announces 1-for-12 reverse stock split

Calidi (CLDI) Biotherapeutics announced that it will effect a reverse stock split of its outstanding shares of common stock at a ratio of 1-for-12. The company’s common stock is expected to commence trading on a split-adjusted basis when the NYSE American market opens on August 5 under the existing symbol of “CLDI.” The new CUSIP number for the company’s common stock following the reverse stock split will be 320703 408.